Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 safety and dose-finding study of YM150 versus warfarin in non-valvular atrial fibrillation
2007-001150-87Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of darexaban in Atrial fibrillation (AFib) (2 arms), sponsored by Astellas Pharma. Primary endpoint: Incidence of major and clinically relevant non-major bleeding events. Started Feb 2009; status: completed.
02
Drugs
darexaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2007-001150-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001150-87.